

PARTICIPATING FACULTY

The Next Era of Anticoagulation Therapy

This supplement to *The American Journal of Managed Care* contains information on anticoagulation therapy for the treatment of atrial fibrillation.

Chairs

Charles S. Abrams, MD

Associate Professor of Medicine
Division of Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Geno J. Merli, MD

Ludwig A. Kind Professor of Medicine
Vice Chairman for Clinical Affairs
Director, Division of Internal Medicine
Senior Associate Dean for Continuing
Medical Education
Jefferson Medical College
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

Faculty

Khalid Abusaada, MD

Resident, Department of Medicine
Drexel University School of Medicine
Philadelphia, Pennsylvania

Cheryl D. Bushnell, MD, MHS

Assistant Professor
Department of Medicine (Neurology)
Duke Center for Cerebrovascular Disease
Senior Fellow
Center for Clinical Health Policy Research
Duke University Medical Center
Durham, North Carolina

Michael D. Ezekowitz, MD, PhD

June F. Klinghoffer Professor
Cardiovascular Medicine Department
Drexel University School of Medicine
Philadelphia, Pennsylvania

Alan S. Go, MD

Physician Scientist and Senior Physician
Division of Research
Kaiser Permanente of Northern California
Oakland, California

Radhika Jaladi, MD

Department of Medicine (Cardiovascular Research)
Drexel University School of Medicine
Philadelphia, Pennsylvania

David B. Matchar, MD

Professor of Medicine and Director
Center for Clinical Health Policy Research
Duke University Medical Center
Staff Physician
Durham VA Medical Center
Durham, North Carolina

Martin O'Donnell, MB

Research Fellow
Henderson Research Centre
McMaster University
Hamilton, Ontario
Canada

Sushant B. Sharma, MD

Department of Medicine (Cardiovascular Research)
Drexel University School of Medicine
Philadelphia, Pennsylvania

Jeffrey I. Weitz, MD

Professor of Medicine and Biochemistry
Henderson Research Centre
Canada Research Chair (Tier 1)
in Thrombosis
Heart and Stroke Foundation
J.F. Mustard Chair in Cardiovascular Research
McMaster University
Hamilton, Ontario
Canada

FACULTY DISCLOSURE

It is policy at the University of Pennsylvania School of Medicine for faculty participating in continuing medical education activities to disclose to participants any significant financial interest or other relationship(s) maintained with a commercial company that has provided financial support for the activity, or whose products or services may be related to the subject matter of the educational content.

The intent of this disclosure is to allow participants to form their own judgments about the educational content of this activity with a full disclosure of the facts. It remains for participants to determine whether a faculty member's interest or relationships may have influenced the presentation in either the exposition or the conclusions presented.

It is policy at *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following faculty have reported receiving something of value* from the commercial supporter(s) of this activity or from a corporate organization whose product(s) may have relevance to the content of their presentations:

■ **Charles S. Abrams, MD**

Consultant To:
Berlex Laboratories
GlaxoSmithKline

■ **Michael D. Ezekowitz, MD, PhD**

Consultant To/ Grant/Research Support From:
AstraZeneca

■ **David B. Matchar, MD**

Speaker's Bureau For:
AstraZeneca

■ **Geno J. Merli, MD**

Grant/Research Support From:

AstraZeneca
Aventis
Bayer
Bristol-Myers Squibb

Speaker's Bureau For:

AstraZeneca
Aventis

■ **Jeffrey I. Weitz, MD**

Consultant To/Received Honoraria From:
AstraZeneca

The following faculty have reported no commercial support:

■ **Khalid Abusaada, MD**

■ **Alan S. Go, MD**

■ **Martin O'Donnell, MB**

■ **Cheryl D. Bushnell, MD, MHS**

■ **Radhika Jaladi, MD**

■ **Sushant B. Sharma, MD**

Investigational and/or Off-Label Use of Commercial Products and Devices

The University of Pennsylvania School of Medicine requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.

The following information was provided by the faculty:

Faculty	Product	Investigational and/or off-label use
Geno J. Merli, MD	Idraparinux	Not yet approved by the FDA
Geno J. Merli, MD	Ximelagatran	Not yet approved by the FDA

*Something of value refers to any equity position, receipt of royalties/honoraria, funding of a research grant, consultations, or to any other relationship with a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policies.